| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 5.57▲ | 5.64▼ | 5.62▼ | 5.97▼ | 5.82▼ |
| MA10 | 5.59▼ | 5.62▼ | 5.70▼ | 6.02▼ | 5.58▲ |
| MA20 | 5.63▼ | 5.73▼ | 5.83▼ | 5.96▼ | 5.32▲ |
| MA50 | 5.63▼ | 5.91▼ | 6.01▼ | 5.50▲ | 6.52▼ |
| MA100 | 5.70▼ | 6.00▼ | 6.02▼ | 5.31▲ | 7.90▼ |
| MA200 | 5.82▼ | 6.01▼ | 5.85▼ | 6.19▼ | 15.11▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.007▼ | 0.002▲ | -0.021▼ | -0.063▼ | 0.184▲ |
| RSI | 39.870▼ | 35.778▼ | 35.296▼ | 45.761▼ | 48.690▼ |
| STOCH | 19.614▼ | 41.345 | 21.864 | 38.987 | 70.541 |
| WILL %R | -74.074 | -83.871▼ | -83.871▼ | -90.521▼ | -39.792 |
| CCI | -51.737 | -74.537 | -87.470 | -144.055▼ | 49.868 |
|
Monday, November 03, 2025 05:00 AM
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the completion of enrollment for ECLIPSE 1, a Phase 3 trial evaluating the safety and efficacy of the combination of tobevibart and elebsiran in ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 03/11/25 | 5.91 | 5.97 | 5.50 | 5.60 | 1,523,592 |
| 31/10/25 | 5.87 | 5.98 | 5.76 | 5.96 | 1,006,327 |
| 30/10/25 | 5.81 | 6.1211 | 5.785 | 5.93 | 1,320,163 |
| 29/10/25 | 6.45 | 6.50 | 5.87 | 5.91 | 1,517,347 |
| 28/10/25 | 6.15 | 6.555 | 6.14 | 6.43 | 1,649,252 |
| 27/10/25 | 5.98 | 6.20 | 5.915 | 6.19 | 986,625 |
| 24/10/25 | 5.85 | 6.025 | 5.81 | 5.98 | 1,415,169 |
| 23/10/25 | 6.09 | 6.19 | 5.745 | 5.78 | 4,663,286 |
| 22/10/25 | 6.21 | 6.29 | 6.08 | 6.12 | 1,292,976 |
| 21/10/25 | 6.28 | 6.44 | 6.12 | 6.27 | 1,009,610 |
|
|
||||
|
|
||||
|
|